Search and Browse
Download
Enter Data
| Reaction Details | |||
|---|---|---|---|
 | Report a problem with these data | ||
| Target | Serine/threonine-protein kinase mTOR | ||
| Ligand | BDBM50433033 | ||
| Substrate/Competitor | n/a | ||
| Meas. Tech. | ChEMBL_955789 (CHEMBL2379606) | ||
| Ki | 13±n/a nM | ||
| Citation |  Cheng, H; Hoffman, JE; Le, PT; Pairish, M; Kania, R; Farrell, W; Bagrodia, S; Yuan, J; Sun, S; Zhang, E; Xiang, C; Dalvie, D; Rahavendran, SV Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series. Bioorg Med Chem Lett23:2787-92 (2013) [PubMed] Article | ||
| More Info.: | Get all data from this article, Assay Method | ||
| Serine/threonine-protein kinase mTOR | |||
| Name: | Serine/threonine-protein kinase mTOR | ||
| Synonyms: | FK506-binding protein 12-rapamycin complex-associated protein 1 | FKBP12-rapamycin complex-associated protein | FRAP | FRAP 1 (mTOR) | FRAP1 | FRAP2 | MTOR | MTOR_HUMAN | Mammalian Target of Rapamycin (mTOR) | P42345 | RAFT1 | RAPT1 | Rapamycin and FKBP12 target 1 | Rapamycin target protein | Serine/threonine-protein kinase (mTOR) | mTORC2 | ||
| Type: | Rapamycin target protein | ||
| Mol. Mass.: | 288917.12 | ||
| Organism: | Homo sapiens (Human) | ||
| Description: | P42345 | ||
| Residue: | 2549 | ||
| Sequence: |
| ||
| BDBM50433033 | |||
| n/a | |||
| Name | BDBM50433033 | ||
| Synonyms: | CHEMBL2376095 | ||
| Type | Small organic molecule | ||
| Emp. Form. | C21H25N5O4 | ||
| Mol. Mass. | 411.4543 | ||
| SMILES | COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@@H]2CC[C@@H](CC2)OCO)c1=O |r,wD:19.20,22.27,(23.9,-1.62,;22.57,-.85,;21.24,-1.62,;19.89,-.85,;18.57,-1.62,;18.56,-3.15,;19.9,-3.93,;21.23,-3.16,;17.23,-3.91,;15.88,-3.12,;14.54,-3.9,;13.21,-3.14,;13.2,-1.6,;11.88,-3.91,;11.87,-5.45,;10.54,-6.22,;13.21,-6.22,;14.54,-5.46,;15.88,-6.23,;15.87,-7.77,;17.2,-8.54,;17.19,-10.08,;15.85,-10.85,;14.52,-10.07,;14.53,-8.53,;15.84,-12.39,;14.5,-13.15,;13.17,-12.37,;17.22,-5.46,;18.56,-6.24,)| | ||
| Structure | 
| ||